{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"73.6","value":"101"},{"groupId":"OG001","spread":"23.0","value":"89.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Week 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.6","value":"107"},{"groupId":"OG001","spread":"34.0","value":"119"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.0","value":"144"},{"groupId":"OG001","spread":"81.9","value":"155"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.1","value":"155"},{"groupId":"OG001","spread":"47.0","value":"171"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.0","value":"172"},{"groupId":"OG001","spread":"49.7","value":"175"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.6","value":"146"},{"comment":"Per plan, data was not summarized when overall number of participants analyzed was less than 3. Therefore, participant wise data is reported in separate OM.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Week 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.0","value":"44.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 84"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Serum concentration of cetrelimab were reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with CIS with or without papillary disease, received TAR-200 intravesically every 3 weeks (Q3W) from Week 0 for the first 24 weeks, followed by every 12 weeks (Q12W) dosing through Week 99 in combination with cetrelimab 360 milligrams (mg) intravenously (IV) Q3W from Week 0 through Week 78. TAR-200 was inserted intravesically via the urinary placement catheter (UPC).","id":"OG000","title":"Cohort 1: TAR-200 + Cetrelimab (CIS With or Without Papillary Disease)"},{"description":"Participants with CIS with or without papillary disease, received cetrelimab 360 mg IV Q3W from Week 0 through Week 78.","id":"OG001","title":"Cohort 3: Cetrelimab IV Monotherapy (CIS With or Without Papillary Disease)"}],"paramType":"MEAN","populationDescription":"FAS included all enrolled participants who received at least 1 dose of study treatment. Here \"N\" (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure, \"n\" (number analyzed) signifies number of participants evaluable at specific timepoints. n=0 indicated that this time point was not applicable for this arm. This OM was planned to be analyzed for Cohorts 1 and 3 only.","reportingStatus":"POSTED","timeFrame":"At Weeks 0, 3, 12, 24, 48, 60, 84 (end of infusion) [EOI]","title":"Cohort 1and 3: Serum Concentration of Cetrelimab","type":"SECONDARY","unitOfMeasure":"mcg/mL"}